---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054442"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:45:48.654470+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M

## Summary
- STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.
- Suspended all mavodelpar development; reduced workforce by ~90% in Dec 2023 and Feb 2024.
- Retained independent financial advisor to explore strategic alternatives, including possible sale.
- Q1 2024 net loss $8.4M ($0.25/share) vs $15.1M ($0.60/share) Q1 2023; cash $82.8M as of Mar 31, 2024.
- R&D expenses fell to $4.9M from $11.0M due to program suspension and cost-cutting.

## SEC filing metadata
- accession: 0000950170-24-054442
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/rphm-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054442
- JSON: https://secwatch.observer/filing/0000950170-24-054442.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054442.txt

## Key facts
- Earnings Releases
  OnKure Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $8.4 million, or $0.25 per share, EPS $0.25 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: net loss of $8.4 million, or $0.25 per share
  - EPS: $0.25 per share
  - Result: reported results
  source text: We reported a net loss of $8.4 million, or $0.25 per share, during the first quarter of 2024, compared to a net loss of $15.1 million, or $0.60 per share, for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1637715/000095017024054442/0000950170-24-054442-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.